Alumis
Signal active
Organization
Contact Information
Overview
Alumis develops precision medications to treat autoimmune illnesses. The company's analytics platform and understanding of immunologic disorders aid in the development of treatments and medications for autoimmune diseases, allowing patients to alleviate suffering and modify their way of life.
About
Industries
Biotechnology, Life Science, Health Care, Precision Medicine
Founded
2021
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Alumis headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Precision Medicine sector. The company focuses on Biotechnology and has secured $25.4B in funding across 48 round(s). With a team of 11-50 employees, Alumis is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Alumis, raised $259.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
12
Lead Investors
0
Total Funding Amount
$529.0M
Details
3
Alumis has raised a total of $529.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 70.0M | ||
| 2022 | Early Stage Venture | 200.0M | ||
| 2024 | Late Stage Venture | 259.0M |
Investors
Alumis is funded by 25 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Piper Heartland Healthcare Capital | - | FUNDING ROUND - Piper Heartland Healthcare Capital | 259.0M |
| HBM Healthcare Investments | - | FUNDING ROUND - HBM Healthcare Investments | 259.0M |
| Alumis | - | FUNDING ROUND - Alumis | 259.0M |
| Nextech | - | FUNDING ROUND - Nextech | 259.0M |
Recent Activity
There is no recent news or activity for this profile.